Beta thalassemia is an inherited blood disorder in which the patient’s body doesn't make hemoglobin normally. Hemoglobin is the part of red blood cells (RBCs) that carries oxygen throughout the human body. The abnormal hemoglobin can lead to anemia (not enough RBCs in the body) and other medical problems weakness, shortness of breath. Depending on the type of beta thalassemia, symptoms can be mild or very severe. Moreover, clinically there can be two main categories of beta-thalassemia patients based on the patient's need for blood transfusion transfusion-dependent thalassemia (TDT) and non-transfusion dependent thalassemia (NTDT). The diagnosis of beta thalassemia relies on measuring red blood cell indices that reveal microcytic hypochromic anemia, nucleated red blood cells on peripheral blood smear, hemoglobin analysis that reveals decreased amounts of HbA and increased amounts of hemoglobin F (HbF) after age of 12 months.
The global beta-thalassemia (B-thal) market is estimated to be valued at US$ 411.8 million in 2021 and is expected to exhibit a CAGR of 7.8% over the forecast period (2021-2028).
Figure 1. Global Beta-thalassemia (B-thal) Market Share (%), By Region, 2021
To learn more about this report, request a free sample copy
The increasing incidence of beta-thalassemia is expected to drive the growth of the global beta-thalassemia (B-thal) market over the forecast period.
Rising number of patient population suffering from beta-thalassemia globally is anticipated to drive the market growth over the forecast period.
For instance, according to the report published by Bristol-Myers Squibb Company, a global biopharmaceutical company, in November 2018, stated that about 1.5% of the global population (an estimated 80-90 million people) are carriers of β-thalassemia. Although β-thalassemia is relatively rare in the U.S., there are an estimated 1.25 million carriers, making up 0.4% of the population. Moreover, according to the same source, thalassemia affects about 2,000 patients living in the U.S., with 1,000 patients having β-thalassemia major.
For instance, according to the article published in the Journal of European Hematology Association in June 2019, stated that the annual incidence of symptomatic individuals suffering from β-thalassemia is estimated at between one in 100,000 worldwide and one in 10,000 in Europe.
Beta-thalassemia (B-thal) Market Report Coverage
|Market Size in 2021:
|US$ 411.8 Mn
|Historical Data for:
|2017 to 2020
|2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
|2028 Value Projection:
|US$ 698.3 Mn
Celgene Corp., BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Orchard Therapeutics, Sangamo Therapeutics, CRISPR Therapeutics, DisperSol Technologies, Kiadis Pharma, Incyte Corporation, Editas Medicine, Global Blood Therapeutics, and Syros Pharmaceuticals
|Restraints & Challenges:
Figure 2. Global Beta-thalassemia (B-thal) Market Value (US$ Mn), By Treatment, 2021
To learn more about this report, request a free sample copy
The increasing research and development activities for the development and approval of novel therapeutics for the treatment of beta-thalassemia is expected to drive the market growth over the forecast period.
Key players operating in the market are focusing on submitting application for approval of drugs therapy for the treatment of beta-thalassemia, which is expected to drive growth of the global beta-thalassemia (B-thal) market over the forecast period.
For instance, in September 2021, Bluebird bio, a U.S. based biotechnology company, announced that its beti-cel gene therapy had been officially submitted for approval in the U.S., for the treatment of beta-thalassemia. Beti-cel was tested in multiple early- and late-stage clinical trials as a one-time treatment for beta-thalassemia, a rare condition that impairs the production of hemoglobin, the oxygen-carrying protein in red blood cells. Bluebird bio, a biopharmaceutical company is submitted the approval letter to the Food and Drug Administration to approve its therapy for adults and children with beta-thalassemia who need regular transfusions of red blood cells. Beti-cel is already cleared for market in Europe, where it's sold under the brand name Zynteglo.
Furthermore, in November 2019, the U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept–aamt) for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Global Beta-thalassemia (B-thal) Market – Impact of Coronavirus (Covid-19) Pandemic
During this COVID-19 pandemic, pharmaceutical business, clinical tool companies and likewise biotechnology firms are facing difficulties that are occurring from the interruption in supply chains and the demand to transform service processes. As the researches reveal that there is no relationship in between beta-thalassemia as well as coronavirus, hence beta-thalassemia market is being affected by the pandemic. If COVID-19 pandemic proceeds for a medium/long duration, it may impact the supply of product and also active ingredients around the world along with the import as well as export of drugs. There has been a disturbance in the treatment market. As coronavirus has actually ended up being the major emphasis on beta-thalassemia market and all study institutes, biotech as well as pharmaceutical companies are selected in cooperation job to manage COVID-19, who are previously engaged in research and development of therapeutics for the treatment of beta-thalassemia.
Global Beta-thalassemia (B-thal) Market Restraint
The strict pricing and reimbursement policies, high cost of drugs used in the treatment of beta-thalassemia are the factors that are expected to hinder growth of the global beta-thalassemia market over the forecast period.
Major players operating in the global beta-thalassemia (B-thal) market include Celgene Corp., BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Orchard Therapeutics, Sangamo Therapeutics, CRISPR Therapeutics, DisperSol Technologies, Kiadis Pharma, Incyte Corporation, Editas Medicine, Global Blood Therapeutics, and Syros Pharmaceuticals.
Frequently Asked Questions